Asymchem (凯莱英)
Tianjin CDMO best known for small-molecule continuous-flow chemistry, now pivoting hard into peptide/GLP-1 "chemical macromolecule" capacity.
1. Core Product / Service
Asymchem (凯莱英, founded 1999, Tianjin) is a CDMO. Its core is small-molecule CDMO, where it built a reputation on continuous-flow chemistry; its growth engine is the "chemical macromolecule" line — peptides, oligonucleotides, ADCs and lipids — where GLP-1 demand is the driver [1]. The company has signed GLP-1 peptide commercialization orders and helped a domestic client's GLP-1 peptide project pass dynamic regulatory inspection toward first commercial supply [1].
2. Target Users & Pain Points
Big pharma and biotech outsourcing clinical/commercial manufacturing, plus GLP-1 and peptide developers needing solid-phase synthesis capacity — the same TIDES/peptide bottleneck that wuxi-apptec is scaling into [1].
3. Competitive Landscape
| Player | Type | Vs. Asymchem |
|---|---|---|
| wuxi-apptec | Full-stack CRDMO + TIDES | Larger peptide capacity, broader services |
| Asymchem | CDMO (small molecule + peptides) | Continuous-flow strength, peptide pivot |
| pharmaron | Integrated CRO/CDMO | More lab-services skew, smaller CMC |
| Lonza / Bachem / PolyPeptide | Western CDMO / peptide specialists | Incumbent peptide CDMOs |
4. Unique Observations
- One of China's two big peptide capacity bets. Alongside wuxi-apptec's TIDES unit, Asymchem's chemical-macromolecule line is the other major Chinese capacity build-out aimed at GLP-1 peptides: backlog +130% YoY and solid-phase capacity planned to rise from ~21,000 L to 30,000 L [1].
- The COVID-order hangover. 2024 revenue fell 25.8% only because 2023 contained a one-off COVID commercial order; excluding it, revenue grew ~7.4% — a reminder that CDMO headline numbers need one-off orders stripped out before reading the trend [1].
5. Financials / Funding
- FY2024 revenue: RMB 5.81B (−25.8% YoY; +7.4% excluding the 2023 large order); net profit RMB 949M (−58.2%) [1].
- Small-molecule CDMO RMB 4.57B (commercial-stage RMB 2.80B; clinical-stage RMB 1.77B, +17.2% ex-large-orders) [1].
- Chemical-macromolecule segment (peptides/oligos/ADC/lipids): +13.26% YoY in 2024; backlog +130% YoY; peptide solid-phase capacity ~21,000 L end-2024 → 30,000 L planned for H2 2025 [1].
- Listed: SZSE 002821.SZ and HKEX 6821.HK [1].
6. People & Relationships
- Founder & Chairman: Dr. Hao Hong (洪浩) [1].
- Peers / competitors: wuxi-apptec, pharmaron, Lonza, Bachem, PolyPeptide.
Sources
[1] Asymchem 2024 annual report announcement, HKEX (stock code 6821), https://www.hkexnews.hk/listedco/listconews/sehk/2025/0328/2025032804610_c.pdf (2026-10-19).